Risk of depression and dementia among individuals treated with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

Summary: New research suggests that popular diabetes medications—specifically SGLT2 inhibitors and GLP-1 receptor agonists (like those used in Ozempic)—might offer benefits for the brain beyond blood sugar control. Recent studies indicate these drugs could lower the risk of developing dementia and cognitive impairment in later life. SGLT2 inhibitors also show promise in reducing depression. However, the news isn't entirely positive; there are lingering concerns and inconsistent data regarding GLP-1 agonists and a potential increased risk of suicidal thoughts. While the cognitive protection looks promising, experts warn that prescription biases might be influencing the data, and robust clinical trials are needed to confirm safety and effectiveness.